UK Medical Cannabis Registry: a case series analysing clinical outcomes of medicinal cannabis therapy for fibromyalgia - Takeaways - MDSpire

UK Medical Cannabis Registry: a case series analysing clinical outcomes of medicinal cannabis therapy for fibromyalgia

  • By

  • Madhur Varadpande

  • Simon Erridge

  • Arushika Aggarwal

  • Evonne Clarke

  • Katy McLachlan

  • Ross Coomber

  • Shelley Barnes

  • Alia Darweish Medniuk

  • Rahul Guru

  • Wendy Holden

  • Mohammed Sajad

  • Robert Searle

  • Azfer Usmani

  • Sanjay Varma

  • James J. Rucker

  • Michael Platt

  • Mikael H. Sodergren

  • December 4, 2025

  • 0 min

Share

  • 1

    Fibromyalgia affects 5.4% of adults, primarily women, and is characterized by chronic pain, fatigue, and cognitive issues.

  • 2

    Current treatments for fibromyalgia, including pregabalin and antidepressants, often have limited efficacy and high discontinuation rates.

  • 3

    Cannabis-based medicinal products (CBMPs) show promise for fibromyalgia, with observational studies indicating improvements in pain and quality of life.

  • 4

    The UK Medical Cannabis Registry collects data on CBMP outcomes, providing insights into patient-reported outcomes and adverse events.

  • 5

    This case series aims to evaluate the effectiveness of CBMPs in fibromyalgia patients, highlighting the need for further research in this area.

Original Source(s)

Related Content